Medical Device Network on MSN7d
Foresight announces trial launch for cHL treatment with ctDNA-based MRD test
Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...
Zacks Investment Research on MSN3d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Medscape21d
Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
GlobalData on MSN16d
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab) combo as a first ...
Yahoo Finance28d
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
RELATIVITY-098 is a randomized Phase 3, double-blind study evaluating adjuvant immunotherapy with Opdualag, the fixed-dose combination of nivolumab and relatlimab, compared to Opdivo monotherapy ...
Medscape10d
1 in 5 Patients Experience Skin Toxicity With Nivolumab/Relatlimab
In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...